While looking at the 10-Q yesterday, I noticed it
Post# of 148323
"As of November 30, 2018 and May 31, 2018, the Company did not have pre-launch inventory that qualified for capitalization pursuant to U.S. GAAP ASC 330 “Inventory.”
"The determination to capitalize is made once the Company (or its third party development partners) has filed a Biologics License Application (“BLA”) that has been acknowledged by the FDA as containing sufficient information to allow the FDA to conduct its review in an efficient and timely manner and
management is reasonably certain that all regulatory and legal requirements will be satisfied."
Based on my understanding if we do not receive an up-front payment from a license deal before the BLA is filed, capitalizing the inventory should be enough to meet the $4M equity requirement......now we just need to get the SP at $2+ for 90 days to be eligible to up-list late 2019.